ENDRA Life Sciences NDRAU 深 沪
等待开盘 01-29 09:30:00 美东时间
4.50
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.50
- 总市值 1490.87万
- 52周最高 5.59
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.01
- 委 比 0.00%
- 总股本 331.30万
- 历史最高 5.59
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.01
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ENDRA Life Sciences Announces New Results From 2025 TAEUS Liver Device Feasibility Study Showing TAEUS' TAFF Measurement Closely Tracks MRI-PDFF Gold Standard At Critical LFF Thresholds Of 12-17% And 20-22%
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoringENDRA Life Sciences Inc. (NASDAQ:NDRA)
2025-12-04 21:03
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(2.10) per share which missed the analyst consensus estimate of $(1.95) by 7.69 percent. This is a 77.99 percent increase over losses of $(9.54) per share
2025-11-17 21:20
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
2025-11-13 01:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
2025-10-15 01:06
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced $4.9M in funding to launch a digital asset treasury strategy.
2025-10-14 00:24
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.
2025-09-22 17:54
ENDRA Life Sciences Q2 EPS $(1.71) Beats $(2.27) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(2.27) by 24.67 percent. This is a 2037.5 percent decrease over losses of $(0.08) per share
2025-08-15 04:17
快讯 | ENDRA生命科学公司第二季度运营支出为120万美元
ENDRA Life Sciences Q2 Operating Expenses USD 1.2 Million
2025-08-15 04:05
ENDRA Life Sciences Launches Bitcoin Treasury Strategy, Forms Advisory Board With James Altucher, James Manning, And Rayne Steinberg
The Board of Directors (the "Board") of ENDRA Life Sciences Inc. (the "Company") has authorized the Company to develop and pursue a cryptocurrency treasury strategy. Following this authorization, the Company has:
2025-07-23 21:08
快讯 | ENDRA Life Sciences Inc - 预计2025年第二季度没有营业收入 - SEC文件
ENDRA Life Sciences Inc - Expects No Revenue for Q2 2025 - SEC Filing
2025-07-10 04:52
